IDiyas

For the Inventor, By the Inventor

Sugar Land, TX, United States of America

Michael J Soth

USPTO Granted Patents = 20 

 

 

Average Co-Inventor Count = 7.4

ph-index = 6

Forward Citations = 105(Granted Patents)


Company Filing History:

goldMedal20 out of 5,444 
 
University of Texas System
 patents

Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):
1. 12252480 - Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide (2025-03-18),
2. 12186324 - Imidazopiperazine inhibitors of transcription activating proteins (2025-01-07),
3. 11958849 - GLS1 inhibitors for treating disease (2024-04-16),
4. 11713313 - GLS1 inhibitors for treating disease (2023-08-01),
5. 11603365 - Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide (2023-03-14),
6. 11560366 - Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease (2023-01-24),
7. 11370786 - GLS1 inhibitors for treating disease (2022-06-28),
8. 11173145 - Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase (2021-11-16),
9. 11058688 - Imidazopiperazine inhibitors of transcription activating proteins (2021-07-13),
10. 11046649 - Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase (2021-06-29),
11. 10899769 - Imidazopiperazinone inhibitors of transcription activating proteins (2021-01-26),
12. 10899740 - Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide (2021-01-26),
13. 10766892 - GLS1 inhibitors for treating disease (2020-09-08),
14. 10738043 - GLS1 inhibitors for treating disease (2020-08-11),
15. 10428057 - Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease (2019-10-01),

Title: A Closer Look at Inventor Michael J. Soth - Pioneering Innovations in Disease Treatment

Introduction: Michael J. Soth, a distinguished inventor based in Sugar Land, TX, has made remarkable contributions to the field of medicine with his groundbreaking innovations. With 18 patents to his name, Soth continues to push the boundaries of scientific discovery.

Latest Patents: Soth's latest patents revolve around GLS1 inhibitors for treating diseases, particularly cancer. These compounds and compositions, as outlined in Formula I, have shown promising results in inhibiting GLS1 activity in human and animal subjects. Such innovations hold great potential in revolutionizing disease treatment methods.

Career Highlights: Currently affiliated with the University of Texas System, Soth's expertise and dedication have been instrumental in driving cutting-edge research initiatives. His collaborative efforts have led to significant advancements in the development of novel therapies and treatment modalities.

Collaborations: Throughout his career, Soth has collaborated closely with esteemed colleagues such as Philip Jones and Kang Le. Together, they have championed innovative approaches to addressing critical healthcare challenges and improving patient outcomes.

Conclusion: Inventor Michael J. Soth stands as a beacon of innovation in the realm of disease treatment, with a track record of transformative inventions that have the potential to shape the future of healthcare. His relentless pursuit of scientific excellence serves as an inspiration to aspiring inventors and researchers worldwide, cementing his legacy as a trailblazer in the field of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…